Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Deruxtecan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250928521193/en/ENHERTU-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Invasive-Disease-Free-Survival-Versus-T-DM1-in-DESTINY-Breast05-Phase-3-Trial-in-Patients-with-High-Risk-Early-Breast-Cancer-Following-Neoadjuvant-Therapy

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer
    ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer

    24 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250924346850/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-granted-Priority-Review-in-the-US-as-1st-line-treatment-for-patients-with-HER2-positive-metastatic-breast-cancer

    BUSINESSWIRE
    24 Sep 2025
    Share Share
    FDA Grants BTD To R-DXd For Platinum-Resistant Ovarian Cancers
    FDA Grants BTD To R-DXd For Platinum-Resistant Ovarian Cancers

    16 Sep 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/fda-grants-breakthrough-therapy-designation-to-r-dxd-for-platinum-resistant-ovarian-and-related-cancers-17796

    INDPHARMAPOST
    16 Sep 2025
    Share Share
    FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6
    FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6

    15 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250915193255/en/Raludotatug-Deruxtecan-Granted-Breakthrough-Therapy-Designation-by-U.S.-FDA-for-Patients-with-CDH6-Expressing-Platinum-Resistant-Ovarian-Primary-Peritoneal-or-Fallopian-Tube-Cancers-Previously-Treated-with-Bevacizumab

    BUSINESSWIRE
    15 Sep 2025
    Share Share
    Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Response
    Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Response

    07 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250907863702/en/Ifinatamab-Deruxtecan-Demonstrated-Clinically-Meaningful-Response-Rates-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-in-IDeate-Lung01-Phase-2-Trial

    BUSINESSWIRE
    07 Sep 2025
    Share Share
    Daiichi, Merck Prepare for Swift Approval Filing
    Daiichi, Merck Prepare for Swift Approval Filing

    07 Sep 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/daiichi-mercks-advanced-lung-cancer-adc-sees-48-response-registrational-trial

    FIERCE BIOTECH
    07 Sep 2025
    Share Share